ReViral Drug Discovery for Respiratory Syncytial Virus (RSV)

ReViral is a UK-based biotechnology company with a portfolio of drugs to treat Respiratory Syncytial Virus (RSV) infection. RSV currently represents a major unmet medical need in children, the elderly and the immunocompromised.

Our most advanced programme, RV521, is a highly potent, orally-administered inhibitor of RSV fusion protein, and has demonstrated top-line safety and pharmacokinetic data in Phase 1 single and multiple ascending dose (SAD and MAD) trials. RV521 has successfully completed a Phase 2a proof-of-concept study in adult volunteers. RV521 will start clinical trials in patients in 2018.

RV521 best-in-class drug to treat RSV infections
  • RV521 is an orally available antiviral with excellent drug-like characteristics
  • Binds to the RSV fusion protein, blocking viral entry and preventing cell-to-cell spread
  • The compound demonstrates potent activity against multiple clinical strains of RSV

RSV Medical Need

  • RSV is the main cause of hospitalisation for children under the age of 5 and a major cause of hospitalisation for the elderly
  • Currently, there are no effective treatments or vaccines available against RSV
  • There is a clear unmet need for a safe and effective treatment with a simple route of administration
Meet the team...
Latest News
Virology position available at ReViral

We are recruiting for a practical laboratory-based position and are looking for an experienced graduate level scientist.  The role requires strong communication skills...

Presentation at the American Thoracic Society

ReViral is pleased to announce that Professor John DeVincenzo from the Department of Pediatrics, University of Tennessee, Memphis, USA will be presenting at the American...

ReViral to present at American Chemical Society

ReViral's Chief Scientific Officer, Stuart Cockerill, will be presenting at the American Chemical Society in New Orleans. The afternoon session entitled "MEDI: First Time...

Contact us...